Magle Chemoswed Holding Reports Financial Results For Third Quarter 2025
Magle Group announces its Q3 2025 results, marked by clear progress across key areas of the business.
Q3 2025 KEY INDICATORS
- Net Sales amounted to 71.5 MSEK (64.6)
- EBITDA equaled 33.4 MSEK (26.5)
- Operating profit (EBIT) is 20.3 MSEK (13.8)
- Earnings per share SEK 0.15 (0.89) per share
“The third quarter delivered a stabilised and more aligned performance across the Group, following a challenging Q2. We saw a strong performance from Magle Chemoswed, supported by operational flexibility and sustained demand from Magle Biopolymers. Magle Pharmacept also made solid strategic strides, including international expansion for SmartPAN® and EmboCept® S. While Magle Biopharma continues to face market-driven headwinds, our internal cell therapy development remains a longer-term focus. We are progressing well with our integration and restructuring agenda and remain focused on completing systems alignment and unlocking synergies.” – Justin Pierce, CEO